Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study
Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during remdesivir therapy reaches 66%, with the most common is an increase in liver function tests.The aim of the work was to study the influence of clinica...
Saved in:
Main Authors: | Yu. V. Shevchuk, A. V. Kryukov, I. I. Temirbulatov, I. V. Sychev, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2023-11-01
|
Series: | Фармация и фармакология (Пятигорск) |
Subjects: | |
Online Access: | https://www.pharmpharm.ru/jour/article/view/1355 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predicting the risk of developing drug-induced liver injury during remdesivir therapy in COVID-19 patients using machine learning
by: Yu. V. Shevchuk, et al.
Published: (2024-12-01) -
A Model for Predicting the Risk of Developing Drug-Induced Liver Injury During Therapy with Favipiravir
by: Yu. V. Shevchuk, et al.
Published: (2025-02-01) -
Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
by: Alexandra A. Taube, et al.
Published: (2020-09-01) -
Experience of Using Remdesivir in Patients with Novel Coronavirus Infection
by: V. I. Petrov, et al.
Published: (2022-12-01) -
Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review
by: A. V. Kryukov, et al.
Published: (2022-12-01)